Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
You may also be interested in...
Keeping Track: 2021’s First Novel Approvals Go To HIV And Heart Failure Therapies Opdivo Starts Year With A Bang
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Ipsen CEO Outlines Strategy For Long-Term Success
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Merck’s Keytruda Works With Lenvima In Renal Cancer, But Not With Yervoy In Lung Cancer
Merck’s PD-1 inhibitor combined with Lenvima offered benefit in RCC, but use with Bristol’s Yervoy in metastatic NSCLC showed no benefit compared to Keytruda monotherapy.